HER2-low Breast Cancer: Now and in the Future

키워드

참고문헌 (113)

1. Giaquinto AN, "Breast cancer statistics, 2022", CA Cancer J Clin, 72, pp.524~541 (2022)
2. Modi S, "Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer", N Engl J Med, 387, pp.9~20 (2022)
3. Won HS, "Clinical significance of HER2-low expression in early breast cancer : a nationwide study from the Korean Breast Cancer Society", Breast Cancer Res, 24, pp.22~ (2022)
4. Denkert C, "Clinical and molecular characteristics of HER2-low-positive breast cancer : pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials", Lancet Oncol, 22, pp.1151~1161 (2021)
5. Kang S, "Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy", Eur J Cancer, 176, pp.30~40 (2022)
6. de Moura Leite L, "HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer", Breast Cancer Res Treat, 190, pp.155~163 (2021)
7. Domergue C, "Impact of HER2 status on pathological response after neoadjuvant chemotherapy in early triple-negative breast cancer", Cancers(Basel), 14, pp.2509~ (2022)
8. Tarantino P, "Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer", JAMA Oncol, 8, pp.1177~1183 (2022)
9. Horisawa N, "The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status", Breast Cancer, 29, pp.234~241 (2022)
10. Chen M, "Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression : features of HER2-low breast cancer", Breast Cancer, 29, pp.844~853 (2022)
11. Schettini F, "Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer", NPJ Breast Cancer, 7, pp.1~ (2021)
12. Alves FR, "Impact of human epidermal growth factor receptor 2(HER2)low status in response to neoadjuvant chemotherapy in early breast cancer", Cureus, 14, pp.e22330~ (2022)
13. Agostinetto E, "HER2-low breast cancer : molecular characteristics and prognosis", Cancers(Basel), 13, pp.2824~ (2021)
14. Zhang H, "HER2-low breast cancers : incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles", Mod Pathol, 35, pp.1075~1082 (2022)
15. Jin J, "Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer", J Transl Med, 21, pp.360~ (2023)
16. Tarantino P, "Abstract HER2-05 : HER2-05 comprehensive genomic characterization of HER2-low breast cancer", Cancer Res, 83(5 Suppl), pp.HER2-05~ (2023)
17. Berrino E, "Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas", Genome Med, 14, pp.98~ (2022)
18. Bansal R, "Abstract HER2-12 : HER2-12 genomic and transcriptomic landscape of HER2-low breast cancer", Cancer Res, 83(5 Suppl), pp.HER2-12~ (2023)
19. Marra A, "Abstract HER2-07 : HER2-07 genomic characterization of primary and metastatic HER2-low breast cancers", Cancer Res, 83(5 Suppl), pp.HER2-07~ (2023)
20. Tarantino P, "ESMO expert consensus statements(ECS)on the definition, diagnosis, and management of HER2-low breast cancer", Ann Oncol, 34, pp.645~659 (2023)
21. Tarantino P, "HER2-low inflammatory breast cancer : clinicopathologic features and prognostic implications", Eur J Cancer, 174, pp.277~286 (2022)
22. de Nonneville A, "Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers", Eur J Cancer, 176, pp.181~188 (2022)
23. Di Cosimo S, "Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world", Front Mol Biosci, 9, pp.996434~ (2022)
24. Miglietta F, "HER2-low-positive breast cancer : evolution from primary tumor to residual disease after neoadjuvant treatment", NPJ Breast Cancer, 8, pp.66~ (2022)
25. Peiffer DS, "Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the national cancer database", JAMA Oncol, 9, pp.500~510 (2023)
26. Shao Y, "Clinical, pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting : a retrospective analysis", Ann Surg Oncol, 29, pp.8026~8034 (2022)
27. Molinelli C, "Prognostic value of HER2-low status in breast cancer : a systematic review and meta-analysis", ESMO Open, 8, pp.101592~ (2023)
28. Li Y, "In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer : a study of the National Cancer Center, China", Front Oncol, 11, pp.774577~ (2021)
29. Almstedt K, "Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer", Eur J Cancer, 173, pp.10~19 (2022)
30. Zattarin E, "Prognostic significance of HER2-low status in HR-positive", HER2-negative advanced breast cancer treated with CDK4, NPJ Breast Cancer, pp.2023, 9[DOI]
31. Gampenrieder SP, "Landscape of HER2-low metastatic breast cancer(MBC) : results from the Austrian AGMT_MBC-Registry", Breast Cancer Res, 23, pp.112~ (2021)
32. Jacot W, "Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers", Cancers(Basel), 13, pp.6059~ (2021)
33. Bo J, "Conversion of ER and HER2 status after neoadjuvant therapy in Chinese breast cancer patients", Clin Breast Cancer, 23, pp.436~446 (2023)
34. Kang S, "Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer", Eur J Cancer, 191, pp.112956~ (2023)
35. Ma Y, "Prognostic value of the evolution of HER2-low expression after neoadjuvant chemotherapy", Cancer Res Treat, 55, pp.1210~1221 (2023)
36. Almstedt K, "Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer", Cancers(Basel), 15, pp.1413~ (2023)
37. Anderson S, "The dynamics of HER2-low expression during breast cancer progression", Breast Cancer Res Treat, 201, pp.437~446 (2023)
38. Bergeron A, "Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers", Br J Cancer, 129, pp.122~134 (2023)
39. Cai M, "HER2-low breast cancer : evolution of HER2 expression from primary tumor to distant metastases", BMC Cancer, 23, pp.656~ (2023)
40. Lob S, "Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases", J Cancer Res Clin Oncol, 149, pp.5417~5428 (2023)
41. Miglietta F, "Evolution of HER2-low expression from primary to recurrent breast cancer", NPJ Breast Cancer, 7, pp.137~ (2021)
42. Shang J, "Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer", Front Oncol, 13, pp.1086480~ (2023)
43. Shi Q, "Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression", BMC Cancer, 23, pp.173~ (2023)
44. Tarantino P, "Evolution of low HER2 expression between early and advanced-stage breast cancer", Eur J Cancer, 163, pp.35~43 (2022)
45. Trillo P, "Evolution of biological features of invasive lobular breast cancer : comparison between primary tumour and metastases", Eur J Cancer, 185, pp.119~130 (2023)
46. Denkert C, "Abstract HER2-06 : HER2-06 outcome analysis of HER2-zero or HER2-low hormone receptor-positive(HR+)breast cancer patients-characterization of the molecular phenotype in combination with molecular subtyping", Cancer Res, 83(5 Suppl), pp.HER2-06~ (2023)
47. Turashvili G, "Tumor heterogeneity in breast cancer", Front Med(Lausanne), 4, pp.227~ (2017)
48. Luond F, "Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression", Br J Cancer, 125, pp.164~175 (2021)
49. Polyak K, "Heterogeneity in breast cancer", J Clin Invest, 121, pp.3786~3788 (2011)
50. Kan S, "Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine", Oncol Rep, 34, pp.504~510 (2015)
51. Niikura N, "Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21, 755 patients from the Japanese breast cancer registry", Ann Oncol, 27, pp.480~487 (2016)
52. Gianni L, "Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer", J Clin Oncol, 28, pp.1131~1137 (2010)
53. Nordstrom JL, "Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties", Breast Cancer Res, 13, pp.R123~ (2011)
54. Phase 2 study of the monoclonal antibody MGAH22 (Margetuximab) in patients with relapsed or refractory advanced breast cancer, "National Institutes of Health", ClinicalTrials.gov, ~, pp.NCT01828021 (2022)
55. Burris HA 3rd, "Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2(HER2)-positive breast cancer after prior HER2-directed therapy", J Clin Oncol, 29, pp.398~405 (2011)
56. trastuzumab deruxtecan(DS-8201a), for HER2 cancer therapy, "Chem Pharm Bull(Tokyo)", 2019, 173~185
57. Ogitani Y, "DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1", Clin Cancer Res, 22, pp.5097~5108 (2016)
58. Modi S, "Trastuzumab deruxtecan in previously treated HER2-positive breast cancer", N Engl J Med, 382, pp.610~621 (2020)
59. Andre F, "Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer(DESTINY-Breast02) : a randomised, open-label, multicentre, phase 3 trial", Lancet, 401, pp.1773~1785 (2023)
60. Cortes J, "Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer", N Engl J Med, 386, pp.1143~1154 (2022)
61. Mosele F, "Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression : the phase 2 DAISY trial", Nat Med, 29, pp.2110~2120 (2023)
62. Schmid P, "BEGONIA : phase 1b", 2 study of durvalumab(D)combinations in locally advanced, J Clin Oncol, pp.2021, 39(15 Suppl)[DOI]
63. Hamilton E, "Abstract PD3-07 : trastuzumab deruxtecan(T-DXd; DS-8201)with nivolumab in patients with HER2-expressing, advanced breast cancer : a 2-part, phase 1b, multicenter, open-label study", Cancer Res, 81(4 Suppl), pp.PD3-07~ (2021)
64. Goldenberg DM, "Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan(IMMU-132), an antibody-drug conjugate(ADC)", Oncotarget, 6, pp.22496~22512 (2015)
65. Moon SJ, "Antibody conjugates of 7-ethyl-10-hydroxycamptothecin(SN-38)for targeted cancer chemotherapy", J Med Chem, 51, pp.6916~6926 (2008)
66. Mathijssen RH, "Clinical pharmacokinetics and metabolism of irinotecan(CPT-11)", Clin Cancer Res, 7, pp.2182~2194 (2001)
67. Bardia A, "Sacituzumab govitecan in metastatic triple-negative breast cancer", N Engl J Med, 384, pp.1529~1541 (2021)
68. Hurvitz SA, "168P Sacituzumab govitecan(SG)efficacy in patients with metastatic triple-negative breast cancer(mTNBC)by HER2 immunohistochemistry(IHC)status : findings from the phase III ASCENT study", Ann Oncol, 33(Suppl 3), pp.S200~S201 (2022)
69. Rugo HS, "Sacituzumab govitecan in hormone receptor-positive", human epidermal growth factor receptor 2-negative metastatic breast cancer, 2022, pp.40, 3365~3376
70. Schmid P, "214MO-Sacituzumab govitecan(SG)efficacy in hormone receptor-positive", human epidermal growth factor receptor 2-negative(HR+, Ann Oncol, pp.2022, 33(Suppl 7)[DOI]
71. Tolaney SM, "Final overall survival(OS)analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan(SG)in patients(pts)with hormone receptor–positive", HER2-negative(HR+, J Clin Oncol, pp.2023, 41(16 Suppl)[DOI]
72. "NCCN guidelines version 4.2023, Invasive breast cancer" (2023)[URL]
73. Bartsch R, "Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases : a single-arm, phase 2 trial", Nat Med, 28, pp.1840~1847 (2022)
74. Perez-Garcia JM, "Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer : The DEBBRAH trial", Neuro Oncol, 25, pp.157~166 (2023)
75. Hurvitz S, "Abstract GS3-01: trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03", Cancer Res, 82(4 Suppl), pp.GS3-01~ (2022)
76. Kabraji S, "Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases", Clin Cancer Res, 29, pp.174~182 (2023)
77. Perez-Garcia JM, "Abstract PD7-02 : trastuzumab deruxtecan in patients with unstable central nervous system involvement from HER2-low advanced breast cancer : the DEBBRAH trial", Cancer Res, 83(5 Suppl), pp.PD7-02~ (2023)
78. Epaillard N, "260P Antitumor activity of trastuzumab deruxtecan(T-DXd)in patients with metastatic breast cancer(mBC)and brain metastases(BMs)from DAISY trial", Ann Oncol, 33(Suppl 7), pp.S656~ (2022)
79. Tsurutani J, "388P Subgroup analysis of patients(pts)with HER2-low metastatic breast cancer(mBC)with brain metastases(BMs)at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan(T-DXd)vs treatment of physician’s choice(TPC)", Ann Oncol, 34(Suppl 2), pp.S342~S343 (2023)
80. Dieras V, "Abstract PD13-07 : subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer", Cancer Res, 81(4 Suppl), pp.PD13-07~ (2021)
81. Bardia A, "Abstract GS2-03 : GS2-03 TRIO-US B-12 TALENT : neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer", Cancer Res, 83(5 Suppl), pp.GS2-03~ (2023)
82. Okajima D, "Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells", Mol Cancer Ther, 20, pp.2329~2340 (2021)
83. Bardia A, "LBA11 Datopotamab deruxtecan(Dato-DXd)vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative(HR+", HER2–)breast cancer(BC) : primary results from the rando-mised phase III TROPION-Breast01 trial, 2023, pp.34(Suppl 2), S1264~S1265
84. Bardia A, "Abstract P6-10-03 : datopotamab deruxtecan(Dato-DXd)in advanced triple-negative breast cancer(TNBC) : updated results from the phase 1 TROPION-PanTumor01 study", Cancer Res, 83(5 Suppl), pp.P6-10-03~ (2023)
85. Schmid P, "379MO Datopotamab deruxtecan(Dato-DXd)+ durvalumab(D)as first-line(1L)treatment for unresectable locally advanced", metastatic triple-negative breast cancer(a, II study, pp.Ann Oncol, 2023[DOI]
86. Dent RA, "TROPION-Breast02 : Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer", Future Oncol, 19, pp.2349~2359 (2023)
87. Black J, "SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2", Neu expression, 2016, pp.15, 1900~1909
88. trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer, "Ann Oncol", 2021, S1288~
89. Banerji U, "Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer : a phase 1 dose-escalation and dose-expansion study", Lancet Oncol, 20, pp.1124~1135 (2019)
90. Zhang T, "Abstract LB031 : SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles", Cancer Res, 83(8 Suppl), pp.LB031~ (2023)
91. Skidmore L, "ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers", Mol Cancer Ther, 19, pp.1833~1843 (2020)
92. Zhang J, "Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer", Clin Cancer Res, 28, pp.OF1~OF10 (2022)
93. Xu Y, "Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors", Gastric Cancer, 24, pp.913~925 (2021)
94. Wang J, "RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer : a pooled analysis of two studies", J Clin Oncol, 39(15 Suppl), pp.1022~ (2021)
95. Dhillon S, "Penpulimab : first approval", Drugs, 81, pp.2159~2166 (2021)
96. Geuijen CA, "Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade", Cancer Cell, 33, pp.922~936 (2018)
97. Schram AM, "Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements", Cancer Discov, 12, pp.1233~1247 (2022)
98. Schram AM, "Efficacy and safety of zenocutuzumab, a HER2 × HER3 bispecific antibody, across advanced NRG1 fusion(NRG1+)cancers", J Clin Oncol, 40(16 Suppl), pp.105~ (2022)
99. Pistilli B, "Clinical activity of MCLA-128(zenocutuzumab)in combination with endocrine therapy(ET)in ER+", HER2-low, non-amplified metastatic breast cancer(MBC)patients(pts)with ET-resistant disease who had progressed on a CDK4, 6i), pp.J Clin Oncol, 2020[DOI]
100. Clifton GT, "Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer", Clin Cancer Res, 26, pp.2515~2523 (2020)
101. Chick RC, "Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer", Clin Immunol, 225, pp.108679~ (2021)
102. Jo GS, "The anti-tumor activity of HER-2", neu ICD therapeutic cancer vaccine(AST-301, pNGVL3-hICD)in HER2-expressed gastric can-cer xenograft model, 2021, pp.9(Suppl 2), A811~
103. Fernandez AI, "Examination of low ERBB2 protein expression in breast cancer tissue", JAMA Oncol, 8, pp.1~4 (2022)
104. Hanna W, "Evaluation of HER-2", neu(erbB-2)status in breast cancer : from bench to bedside, 1999, pp.12, 827~834
105. Furrer D, "Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens", Am J Clin Pathol, 144, pp.686~703 (2015)
106. Wolff AC, "Human epidermal growth factor receptor 2 testing in breast cancer", Arch Pathol Lab Med, 147, pp.993~1000 (2023)
107. Wolff AC, "Human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline focused update, 2018, pp.36, 2105~2122
108. Gustavson M, "Abstract PD6-01 : novel approach to HER2 quantification : digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan(T-DXd; DS-8201), specifically in HER2-low patients", Cancer Res, 81(4 Suppl), pp.PD6-01~ (2021)
109. Drago J, "Abstract P2-09-03 : quantification of HER2 expression and spatial biology using computational pathology : a cross-assay validation study in breast cancer", Cancer Res, 83(5 Suppl), pp.P2-09-3~ (2023)
110. Spitzmuller A, "Abstract P6-04-03 : computational pathology based HER2 expression quantification in HER2-low breast cancer", Cancer Res, 83(5 Suppl), pp.P6-04-3~ (2023)
111. Moutafi M, "Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer", Lab Invest, 102, pp.1101~1108 (2022)
112. Abelman RO, "Mechanisms of resistance to antibody-drug conjugates", Cancers(Basel), 15, pp.1278~ (2023)
113. D’Arienzo A, "Toxicity profile of antibody-drug conjugates in breast cancer : practical considerations", EClinicalMedicine, 62, pp.102113~ (2023)

관련 논문AI추천